Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Status: Enrolling
Updated:  3/20/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Status: Enrolling
Updated: 3/20/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas
A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas.
Status: Enrolling
Updated:  3/21/2018
Nationwide Children's Hospital
mi
from
Columbus, OH
A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas
A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas.
Status: Enrolling
Updated: 3/21/2018
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety and Efficacy of Eltrombopag at Escalated Doses
Safety and Efficacy of Eltrombopag at Escalated Doses up to 150mg in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Not Responsive to 75 mg
Status: Enrolling
Updated:  3/21/2018
Weill Cornell Medicine
mi
from
New York, NY
Safety and Efficacy of Eltrombopag at Escalated Doses
Safety and Efficacy of Eltrombopag at Escalated Doses up to 150mg in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Not Responsive to 75 mg
Status: Enrolling
Updated: 3/21/2018
Weill Cornell Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Iron Overload in Stem Cell Transplant Recipients
Impact of Iron Overload in Pediatric Patients Undergoing Stem Cell Transplantation
Status: Enrolling
Updated:  3/22/2018
Children's Hospital Boston
mi
from
Boston, MA
Iron Overload in Stem Cell Transplant Recipients
Impact of Iron Overload in Pediatric Patients Undergoing Stem Cell Transplantation
Status: Enrolling
Updated: 3/22/2018
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Status: Enrolling
Updated:  3/23/2018
Hennepin County Medical Center
mi
from
Minneapolis, MN
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Status: Enrolling
Updated: 3/23/2018
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Status: Enrolling
Updated:  3/23/2018
Hennepin County Medical Center
mi
from
Minneapolis, MN
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Status: Enrolling
Updated: 3/23/2018
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Status: Enrolling
Updated:  3/23/2018
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Status: Enrolling
Updated: 3/23/2018
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Community-Led Action Research in Oncology: Improving Symptom Management
Community-Led Action Research in Oncology: Improving Symptom Management
Status: Enrolling
Updated:  3/23/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Community-Led Action Research in Oncology: Improving Symptom Management
Community-Led Action Research in Oncology: Improving Symptom Management
Status: Enrolling
Updated: 3/23/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Community-Led Action Research in Oncology: Improving Symptom Management
Community-Led Action Research in Oncology: Improving Symptom Management
Status: Enrolling
Updated:  3/23/2018
La Liga Contra el Cancer
mi
from
San Pedro Sula,
Community-Led Action Research in Oncology: Improving Symptom Management
Community-Led Action Research in Oncology: Improving Symptom Management
Status: Enrolling
Updated: 3/23/2018
La Liga Contra el Cancer
mi
from
San Pedro Sula,
Click here to add this to my saved trials
Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction
Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction
Status: Enrolling
Updated:  3/26/2018
Washington University Medical School
mi
from
Saint Louis, MO
Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction
Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction
Status: Enrolling
Updated: 3/26/2018
Washington University Medical School
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
Status: Enrolling
Updated:  3/26/2018
Massachusetts General Hospital
mi
from
Boston, MA
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
Status: Enrolling
Updated: 3/26/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
Mayo Clinic Scottsdale Recruiting
mi
from
Scottsdale, AZ
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
Mayo Clinic Scottsdale Recruiting
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
UC San Diego Moores Cancer Center
mi
from
San Diego, CA
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
UC San Diego Moores Cancer Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
Northwestern University
mi
from
Chicago, IL
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
University of Chicago
mi
from
Chicago, IL
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
University of Michigan
mi
from
Ann Arbor, MI
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
Weill-Cornell Medical College
mi
from
New York, NY
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
MD Anderson Cancer Center, Department of Leukemia
mi
from
Houston, TX
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
MD Anderson Cancer Center, Department of Leukemia
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated:  3/27/2018
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Status: Enrolling
Updated: 3/27/2018
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
HLA-mismatched Allogeneic Cellular Therapy (HMMACT) After Chemotherapy in High Risk Acute Myeloid Leukemia
Status: Enrolling
Updated:  3/28/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
HLA-mismatched Allogeneic Cellular Therapy (HMMACT) After Chemotherapy in High Risk Acute Myeloid Leukemia
Status: Enrolling
Updated: 3/28/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/28/2018
Clinical Research Facility
mi
from
Hazard, KY
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/28/2018
Clinical Research Facility
mi
from
Hazard, KY
Click here to add this to my saved trials
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/28/2018
Clinical Research Facility
mi
from
Rochester, MN
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/28/2018
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/28/2018
Clinical Research Facility
mi
from
Rochester, NY
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/28/2018
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/28/2018
Clinical Research Facility
mi
from
Boston, MA
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/28/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/28/2018
Clinical Research Facility
mi
from
New Brunswick, NJ
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/28/2018
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/28/2018
mi
from
Camperdown,
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/28/2018
mi
from
Camperdown,
Click here to add this to my saved trials
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/28/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/28/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects
A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector (LentiGlobin® BB305 Drug Product)
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Oakland, CA
A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects
A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector (LentiGlobin® BB305 Drug Product)
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Oakland, CA
Click here to add this to my saved trials
A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects
A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector (LentiGlobin® BB305 Drug Product)
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Chicago, IL
A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects
A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector (LentiGlobin® BB305 Drug Product)
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects
A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector (LentiGlobin® BB305 Drug Product)
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Philadelphia, PA
A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects
A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector (LentiGlobin® BB305 Drug Product)
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects
A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector (LentiGlobin® BB305 Drug Product)
Status: Enrolling
Updated:  3/29/2018
mi
from
Sydney,
A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects
A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector (LentiGlobin® BB305 Drug Product)
Status: Enrolling
Updated: 3/29/2018
mi
from
Sydney,
Click here to add this to my saved trials
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS
Phase II Study of 5-azacytidine Maintenance After Allogeneic Hematopoietic Cell Transplantation for High-risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/29/2018
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS
Phase II Study of 5-azacytidine Maintenance After Allogeneic Hematopoietic Cell Transplantation for High-risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/29/2018
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
QST-Pupillometry in Sickle Cell Disease Patients
Quantitative Sensory Testing and Pupillometry in Sickle Cell Disease Patients.
Status: Enrolling
Updated:  3/29/2018
Childrens National Medical Center
mi
from
Washington,
QST-Pupillometry in Sickle Cell Disease Patients
Quantitative Sensory Testing and Pupillometry in Sickle Cell Disease Patients.
Status: Enrolling
Updated: 3/29/2018
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Telomerase Activator and Retinal Amyloid
Evaluation of an Oral Telomerase Activator on Retinal Amyloid
Status: Enrolling
Updated:  3/29/2018
CHippewa Valley Eye Clinic
mi
from
Eau Claire, WI
Telomerase Activator and Retinal Amyloid
Evaluation of an Oral Telomerase Activator on Retinal Amyloid
Status: Enrolling
Updated: 3/29/2018
CHippewa Valley Eye Clinic
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy
Efficacy of a Novel, High-Sensitivity, Portable, Hand-Held Gamma Camera Used Intraoperatively for Identification of Sentinel Lymph Nodes With Lymphoscintigraphy
Status: Enrolling
Updated:  3/29/2018
Stanford University School of Medicine
mi
from
Stanford, CA
Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy
Efficacy of a Novel, High-Sensitivity, Portable, Hand-Held Gamma Camera Used Intraoperatively for Identification of Sentinel Lymph Nodes With Lymphoscintigraphy
Status: Enrolling
Updated: 3/29/2018
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study
Status: Enrolling
Updated:  3/30/2018
Clinical Research Facility
mi
from
Boston, MA
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study
Status: Enrolling
Updated: 3/30/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study
Status: Enrolling
Updated:  3/30/2018
mi
from
Copenhagen Ø,
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study
Status: Enrolling
Updated: 3/30/2018
mi
from
Copenhagen Ø,
Click here to add this to my saved trials
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  3/30/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 3/30/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated:  3/30/2018
University of California at San Francisco
mi
from
San Francisco, CA
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated: 3/30/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated:  3/30/2018
Emory
mi
from
Atlanta, GA
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated: 3/30/2018
Emory
mi
from
Atlanta, GA
Click here to add this to my saved trials
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated:  3/30/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated: 3/30/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated:  3/30/2018
Lahey Hospital and Medical Center
mi
from
Burlington, MA
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated: 3/30/2018
Lahey Hospital and Medical Center
mi
from
Burlington, MA
Click here to add this to my saved trials
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated:  3/30/2018
Rutgers New Jersey Medical School
mi
from
Newark, NJ
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated: 3/30/2018
Rutgers New Jersey Medical School
mi
from
Newark, NJ
Click here to add this to my saved trials
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated:  3/30/2018
Hospital for Special Surgery
mi
from
New York, NY
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated: 3/30/2018
Hospital for Special Surgery
mi
from
New York, NY
Click here to add this to my saved trials
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated:  3/30/2018
Columbia
mi
from
New York, NY
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated: 3/30/2018
Columbia
mi
from
New York, NY
Click here to add this to my saved trials
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated:  3/30/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated: 3/30/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated:  3/30/2018
Metrohealth
mi
from
Cleveland, OH
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated: 3/30/2018
Metrohealth
mi
from
Cleveland, OH
Click here to add this to my saved trials
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated:  3/30/2018
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated: 3/30/2018
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated:  3/30/2018
University of Utah Health Sciences
mi
from
Salt Lake City, UT
Cervical Spondylotic Myelopathy Surgical Trial
Cervical Spondylotic Myelopathy Surgical Trial
Status: Enrolling
Updated: 3/30/2018
University of Utah Health Sciences
mi
from
Salt Lake City, UT
Click here to add this to my saved trials